Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Human Papillomavirus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    138 result(s) found for: Human Papillomavirus. Displaying page 2 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2020-001169-34 Sponsor Protocol Number: HPV_Elimination Start Date*: 2021-03-24
    Sponsor Name:Region Stockholm [...]
    1. Region Stockholm
    2. Region Stockholm
    Full Title: Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden
    Medical condition: HPV infection and related diseases, such as cervical intraepithelial neoplasia grade 2 and 3 and cervical cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    21.1 100000004872 10056576 Cervical intraepithelial neoplasia LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002945-10 Sponsor Protocol Number: V501-020 Start Date*: 2005-02-18
    Sponsor Name:Suomen MSD OY
    Full Title: A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the I...
    Medical condition: Prevention of Human Papillomavirus Infections
    Disease: Version SOC Term Classification Code Term Level
    7.0 10063001 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002083-13 Sponsor Protocol Number: HPVfollowup Start Date*: 2016-07-21
    Sponsor Name:Public Health England
    Full Title: An observational follow up study of a randomised parallel group phase IV study to evaluate the duration of the immune response to vaccine and non-vaccine HPV types in UK adolescent females who rece...
    Medical condition: No specific medical condition - immune reponses to HPV vaccination.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10071146 Human papilloma virus immunisation PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020227-48 Sponsor Protocol Number: 113618 Start Date*: 2011-01-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open-label, multi-centre immunization study to evaluate the safety of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a 0, 1...
    Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18....
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2024-000582-24 Sponsor Protocol Number: V503-024 Start Date*: 2025-01-10
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity and Safety of 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine (V503) in Chinese females 9 to 45 Years of Age
    Medical condition: Papillomavirus Infections
    Disease: Version SOC Term Classification Code Term Level
    27.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2007-003852-13 Sponsor Protocol Number: V504-001-00 Start Date*: 2007-11-09
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus- Like Particle (VLP) Vaccine (V504) Administered Concomitantly with GARDASIL...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52, an...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063001 Human papilloma virus infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-004322-15 Sponsor Protocol Number: V503-IC Start Date*: 2018-02-09
    Sponsor Name:UZ Leuven
    Full Title: An Open-label phase III study to investigate the safety, tolerability and immunogenicity of a nine-valent human papillomavirus (HPV) vaccine (Gardasil®9) in solid organ transplant recipients and HI...
    Medical condition: Immune response to HPV vaccination in HIV-patients and Solid Organ Transplant patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10074286 Immunocompromised LLT
    20.0 100000004848 10020180 HIV positive LLT
    20.0 100000004865 10023438 Kidney transplant LLT
    20.0 100000004865 10007611 Cardiac transplant LLT
    20.0 100000004865 10019248 Heart & lung transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005717-23 Sponsor Protocol Number: V501-018-00 Start Date*: 2015-12-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL™ (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL™ at 9-18 Years of Age
    Medical condition: HPV
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2023-001144-29 Sponsor Protocol Number: V501-213 Start Date*: 2024-01-12
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged ...
    Medical condition: Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003135-36 Sponsor Protocol Number: CYD67 Start Date*: 2019-10-31
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia
    Medical condition: Dengue Fever Dengue Hemorrhagic Fever Human Papillomavirus Disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000060-17 Sponsor Protocol Number: 200255 Start Date*: 2014-05-09
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open-label, non-randomised, multicentre study to assess the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to ...
    Medical condition: Healthy volunteers [For active immunisation of females from 9 years of age onwards for the prevention of persistent infection, premalignant genital (cervical, vulvar and vaginal) lesions and cervic...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10071147 Human papilloma virus immunization LLT
    16.1 100000004848 10058580 Human papilloma virus serology test LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001871-37 Sponsor Protocol Number: LTN0001 Start Date*: 2011-06-06
    Sponsor Name:Department of Infectious Diseases - Aarhus University Hospital
    Full Title: Immune Response to Bivalent or Tetravalent Human Papillomavirus Vaccine in HIV infected Adults
    Medical condition: HIV Human Papilloma Virus
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10020443 Human immunodeficiency virus syndrome LLT
    13.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    13.1 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-004524-65 Sponsor Protocol Number: Inf.Q002 Start Date*: 2015-11-30
    Sponsor Name:Department of Infectious Diseases
    Full Title: Efficacy of nonavalent vaccine against human papilloma virus (HPV ) in HIV infected sexually active men who have sex with men (MSM)
    Medical condition: The purpose of the study is to investigate the efficacy of a new nonavalent HPV vaccine in sexually active HIV-infected MSM.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10063001 Human papilloma virus infection LLT
    18.1 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000369-44 Sponsor Protocol Number: 111375 Start Date*: 2009-03-24
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first v...
    Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000255-50 Sponsor Protocol Number: 207347 Start Date*: 2018-03-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open-label, mono-centre, follow-up extension study to evaluate the persistence of immune response to GSK Biologicals’ HPV vaccine in healthy Chinese female subjects who received three ...
    Medical condition: Healthy volunteers (to evaluate the persistence of immune response in subjects who received the HPV-16/18 vaccine, seven to eight years after the last dose of vaccination in the primary study)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000111-16 Sponsor Protocol Number: V501-029 Start Date*: 2017-01-11
    Sponsor Name:Merck & Co., Inc.
    Full Title: Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in healthy females 9 to 15 years of age in India.
    Medical condition: vaccination against HPV infection/related disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023393-39 Sponsor Protocol Number: GDS01C Start Date*: 2011-01-13
    Sponsor Name:Sanofi Pasteur MSD S.N.C
    Full Title: A Randomized, Double-Blinded, Controlled with GARDASIL® (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Toler...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) Types 6, ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066416 Vulvovaginal human papilloma virus infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: FI (Completed) BE (Completed) SE (Completed) ES (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002951-14 Sponsor Protocol Number: 12/0357 Start Date*: 2016-06-17
    Sponsor Name:University College London
    Full Title: Human papillomavirus infection: a randomised controlled trial of Imiquimod cream (5%) versus Podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccinat...
    Medical condition: Anogenital warts
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059313 Anogenital warts PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018182 Genital warts LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002340-90 Sponsor Protocol Number: HPV-Xneutra-001 Start Date*: 2013-06-26
    Sponsor Name:Ghent University Hospital
    Full Title: Study of the molecular mechanisms underlying the cross-neutralizing capacity of AS04-adjuvanted HPV vaccine (Cervarix®) in comparison with the aluminiumhydroxyphosphate sulphate adjuvanted HPV vacc...
    Medical condition: vaccin against the human papillomavirus
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10046859 Vaccination LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002193-23 Sponsor Protocol Number: HLS04/2011 Start Date*: 2011-09-27
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Long term Immunogenicity of Quadrivalent Human Papillomavirus vaccine (Gardasil) in HIV-infected adolescents and young adults vs. healthy adolescents and young adults: non-randomized controlled cli...
    Medical condition: HIV+ teenagers and young adults versus HIV-negative subjects: high-risk population for HPV-related disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 29 03:31:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA